ESTRING RING (SLOW-RELEASE)
Land: Kanada
Tungumál: enska
Heimild: Health Canada
Vara einkenni
(SPC)
16-11-2017
Sum skjöl fyrir þessa vöru eru ekki tiltæk eins og er, þú getur sent beiðni til þjónustu við viðskiptavini okkar og við munum láta þig vita um leið og við getum fengið þau.
Senda beiðni.
Senda beiðni.
Virkt innihaldsefni:
ESTRADIOL
Fáanlegur frá:
PFIZER CANADA ULC
ATC númer:
G03CA03
INN (Alþjóðlegt nafn):
ESTRADIOL
Skammtar:
2MG
Lyfjaform:
RING (SLOW-RELEASE)
Samsetning:
ESTRADIOL 2MG
Stjórnsýsluleið:
VAGINAL
Einingar í pakka:
1
Gerð lyfseðils:
Prescription
Lækningarsvæði:
ESTROGENS
Vörulýsing:
Active ingredient group (AIG) number: 0106457001; AHFS:
Leyfisstaða:
APPROVED
Leyfisdagur:
2001-04-11
Vara einkenni
_ _
_ESTRING*(17 β-Estradiol) Product Monograph _
_Page 1 of 38 _
PRODUCT MONOGRAPH
PR
ESTRING *
(
17 Β-ESTRADIOL
)
_ _
Vaginal Ring, 2 mg
_ _
_ _
ESTROGEN
Pfizer Canada Inc.
Date of Revision:
17,300 Trans-Canada Highway
November 16, 2017
Kirkland, Quebec H9J 2M5
CONTROL NUMBER: 208652
*TM Pfizer Health AB
Pfizer Canada Inc., Licensee
© Pfizer Canada Inc. 2017
Distributed by: Paladin Labs Inc.
St-Laurent, Quebec, H4M 2P2
_ _
_ESTRING*(17 β-Estradiol) Product Monograph _
_Page 2 of 38 _
TABLE OF CONTENTS
PART 1: HEALTH PROFESSIONAL INFORMATION
.............................................................................................
3
SUMMARY
PRODUCT
INFORMATION
................................................................................................................
3
INDICATIONS
AND
CLINICAL
USE
......................................................................................................................
3
CONTRAINDICATIONS
............................................................................................................................................
3
WARNINGS
AND
PRECAUTIONS
...........................................................................................................................
4
ADVERSE
REACTIONS
...........................................................................................................................................
15
DRUG
INTERACTIONS
...........................................................................................................................................
19
DOSAGE
AND
ADMINISTRATION
.......................................................................................................................
21
OVERDOSAGE
..........................................................................................................................................................
22
ACTION
AND
CLINICAL
PHARMACOLOGY
....................................................................................................
22
STORAGE
AND
STABI
Lestu allt skjalið
